Posts by: Diana Campelo Delgado

Diana Campelo Delgado

Diana holds a PhD in Biomedical Sciences, with specialization in genetics, from Universidade Nova de Lisboa, Portugal. Her work has been focused on enzyme function, human genetics and drug metabolism.

April 12, 2021April 12, 2021

Molecular Link Found Between Parkinson’s and Skin Cancer

News

Researchers have found a molecular link between Parkinson’s disease and melanoma, a type of skin cancer, in the form of protein clumps. Their study results were presented at the spring ... Read more

April 9, 2021April 9, 2021

Health Canada Allows Start of DA01 Trial Testing Cell Therapy

News

BlueRock Therapeutics has received permission from Health Canada to start a Phase 1 clinical trial evaluating DA01, an investigational cell therapy that aims to restore neurons lost to Parkinson’s disease. ... Read more

April 9, 2021April 9, 2021

Phase 2 Trial of Cognitive Treatment NYX-458 Resumes

News

Aptinyx‘s Phase 2 clinical trial evaluating its investigational oral compound NYX-458 for the treatment of cognitive impairment and mild dementia associated with Parkinson’s disease is resuming patient screening after a temporary ... Read more

April 2, 2021April 2, 2021

Magnetic Nanoparticles May Help Restore Brain Function

News

Magnetic nanoparticles may help restore brain function by directing nerve cell growth, a new study shows. Researchers believe this technology has therapeutic potential and may be used in the development of ... Read more

March 30, 2021March 30, 2021

Protein Fragment in CSF Shows Potential as Diagnostic Biomarker

News

A protein fragment known as GPR37 is evident in the cerebrospinal fluid of people with Parkinson’s disease, and may be promising candidate as a biomarker for earlier diagnosis, scientists in Spain ... Read more

March 26, 2021March 26, 2021

Forest Hills Lab Asking to Open Phase 2 Trial of FHL-301 in Parkinson’s

News

Forest Hills Lab announced plans to soon apply to the U.S. Food and Drug Administration (FDA) for permission to open a Phase 2 clinical trial evaluating the tolerability and efficacy of ... Read more

March 25, 2021March 25, 2021

Global PPMI Study Now Enrolling Adults With Parkinson’s Risk Factors

News

The Parkinson’s Progression Markers Initiative (PPMI), a study sponsored by The Michael J. Fox Foundation, is recruiting people with known disease risk factors but no official Parkinson’s diagnosis, the foundation ... Read more

March 24, 2021March 24, 2021

COVID-19 Affected Speech, Language Therapies, UK Survey Shows

News

Lockdown during the COVID-19 pandemic has affected speech and language therapy in patients with Parkinson’s disease, a survey in the United Kingdom shows. The survey was conducted by the Royal ... Read more

March 19, 2021March 19, 2021

Collaboration Tackles Sleep Problems in Parkinson’s

News

Cambridge Sleep Sciences and Parkinson’s Concierge have entered an agreement to tackle sleep problems in Parkinson’s disease. Sleep problems such as difficulty falling asleep, daytime sleepiness, and troubled dreams are among ... Read more

March 16, 2021March 16, 2021

Parkinson’s UK Award Targets New Therapies

News

Researchers at the Sheffield Institute for Translational Neuroscience (SITraN) have been awarded £1.2 million ($1.67 million) from Parkinson’s UK to develop new treatments that slow progression of the disease. “This new funding will ... Read more